title: Gemcitabine-oxaliplatin combination for ovarian cancer resistant to taxane-platinum treatment: a phase II study from the GINECO group.
abstract: Advanced ovarian carcinoma in early progression (<6 months) (AOCEP) is considered resistant to most cytotoxic drugs. Gemcitabine (GE) and oxaliplatin (OXA) have shown single-agent activity in relapsed ovarian cancer. Their combination was tested in patients with AOCEP in phase II study. Fifty patients pre-treated with platinum-taxane received q3w administration of OXA (100 mg m(-2), d1) and GE (1000 mg m(-2), d1, d8, 100-min infusion). Patient characteristics were a : median age 64 years (range 46-79),and 1 (84%) or 2 (16%) earlier lines of treatment. Haematological toxicity included grade 3-4 neutropaenia (33%), anaemia (8%), and thrombocytopaenia (19%). Febrile neutropaenia occurred in 3%. Non-haematological toxicity included grade 2-3 nausea or vomiting (34%), grade 3 fatigue (25%),and grade 2 alopecia (24%). Eighteen (37%) patients experienced response. Median progression-free (PF) and overall survivals (OS) were 4.6 and 11.4 months, respectively. The OXA-GE combination has high activity and acceptable toxicity in AOCEP patients. A comparison of the doublet OXA-GE with single-agent treatment is warranted.
authors.affiliation: Centre Léon Bérard, 28 rue Laennec, 69008 Lyon, France. ray@lyon.fnclcc.fr
authors.forename: I
authors.initials: I
authors.lastname: Ray-Coquard
authors.forename: B
authors.initials: B
authors.lastname: Weber
authors.forename: J
authors.initials: J
authors.lastname: Cretin
authors.forename: Z
authors.initials: Z
authors.lastname: Haddad-Guichard
authors.forename: E
authors.initials: E
authors.lastname: Lévy
authors.forename: A C
authors.initials: AC
authors.lastname: Hardy-Bessard
authors.forename: M C
authors.initials: MC
authors.lastname: Gouttebel
authors.forename: J-F
authors.initials: JF
authors.lastname: Geay
authors.forename: A
authors.initials: A
authors.lastname: Aleba
authors.forename: H
authors.initials: H
authors.lastname: Orfeuvre
authors.forename: C
authors.initials: C
authors.lastname: Agostini
authors.forename: J
authors.initials: J
authors.lastname: Provencal
authors.forename: J M
authors.initials: JM
authors.lastname: Ferrero
authors.forename: D
authors.initials: D
authors.lastname: Fric
authors.forename: N
authors.initials: N
authors.lastname: Dohollou
authors.forename: D
authors.initials: D
authors.lastname: Paraiso
authors.forename: J
authors.initials: J
authors.lastname: Salvat
authors.forename: E
authors.initials: E
authors.lastname: Pujade-Lauraine
mesh_terms: D000368:Aged; D000970:Antineoplastic Agents / Q000008:administration & dosage* / Q000009:adverse effects; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000008:administration & dosage / Q000009:adverse effects; D001952:Bridged-Ring Compounds / Q000008:administration & dosage; D003841:Deoxycytidine / Q000008:administration & dosage / Q000009:adverse effects / Q000031:analogs & derivatives*; D004305:Dose-Response Relationship, Drug; D019008:Drug Resistance, Neoplasm; D005260:Female; D006801:Humans; D008875:Middle Aged; D009944:Organoplatinum Compounds / Q000008:administration & dosage* / Q000009:adverse effects; D010051:Ovarian Neoplasms / Q000188:drug therapy*; D000077150:Oxaliplatin; D010984:Platinum / Q000008:administration & dosage; D043823:Taxoids / Q000008:administration & dosage; D000093542:Gemcitabine
chemical_list: D000970:Antineoplastic Agents; D001952:Bridged-Ring Compounds; D009944:Organoplatinum Compounds; D043823:Taxoids; D000077150:Oxaliplatin; D003841:Deoxycytidine; C080625:taxane; D010984:Platinum; D000093542:Gemcitabine